


DT04 Rec'd PCT/PTO 27 SEP 2004

Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I) or a pharmaceutically acceptable salt thereof:





wherein



R^1 and R^2 independently represent hydrogen or C_{1-6} alkyl or R^1 is linked to R^2 to form a group $(CH_2)_2$, $(CH_2)_3$ or $(CH_2)_4$;

p represents 1 or 2;


m represents an integer from 1 to 4, when m is an integer greater than 1, two R^2 groups may instead be linked to form a group CH_2 , $(CH_2)_2$ or $(CH_2)_3$;

Q represents a group of formula (i), (ii), (iii) or (iv):





wherein [N] and [S] represent the attachment points for the groups



one of X and Y represents $-\text{N}=\text{}$ and the other represents $-\text{N}(\text{R}^5)-$;

R^3 and R^4 independently represent hydrogen, halogen, cyano, $-\text{CF}_3$, $-\text{OCF}_3$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl or a group $-\text{CONR}^6\text{R}^7$;

R^{3a} and R^5 independently represent hydrogen or C_{1-6} alkyl;

R^6 and R^7 independently represent hydrogen or C_{1-6} alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

n and q independently represent 1 or 2;

r and s independently represent an integer from 1 to 3;

A represents a group $-\text{Ar}^1$ or $-\text{Ar}^2\text{Ar}^3$;

Ar^1 , Ar^2 and Ar^3 independently represent an aryl group or a heteroaryl group, both of which may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C_{1-6} alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C_{1-6} alkoxy, aryl C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonyl C_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl C_{1-6} alkyl, C_{1-6} alkylsulfonamido, C_{1-6} alkylamido, C_{1-6} alkylsulfonamido C_{1-6} alkyl, C_{1-6} alkylamido C_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido C_{1-6} alkyl, arylcarboxamido C_{1-6} alkyl, aroyl, aroyl C_{1-6}

alkyl, arylC₁₋₆ alkanoyl, or a group CONR⁸R⁹ or SO₂NR⁸R⁹, wherein R⁸ and R⁹ independently represent hydrogen or C₁₋₆ alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;
or solvates thereof.

2. (Original) A compound according to claim 1 which is a compound of formula E1-E16 or a pharmaceutically acceptable salt thereof.

3. (Amended) A [compound according to claim 1 or claim 2 for use in therapy] pharmaceutical composition which comprises a compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.

4. (Amended) A [compound according to claim 1 or claim 2 for use in the treatment of depression, anxiety, obesity and cognitive memory disorders] method of treating depression, anxiety, obesity and cognitive memory disorders which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.

5. (Canceled)